Drug Trial Radar · NCT01306929
Open-label Extension Study of Pridopidine (ACR16) in the Symptomatic Treatment of Huntington Disease
Last checked: Nov 19, 2026Latest source record: Feb 9, 2022 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
134
Actual
Start
Mar 24, 2011
Primary completion
Jan 5, 2018
Study completion Jan 5, 2018
Sponsor
- Lead sponsor
- PrileniaIndustry
- Sponsor type
- Industry
- First posted
- Mar 2, 2011
Design
- Study type
- Interventional
- Phase
- Phase 2
- Allocation
- Not applicable (single group)
- Model
- Single group
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
Huntington disease (HD) is a hereditary neurodegenerative disorder causing impairment in movement, behavioral dysfunction and dementia. The movement disorder is mainly characterized by chorea (involuntary movements) and a progressive loss of voluntary movement causing a substantial functional impairment over time. The study will assess the long-term safety of pridopidine and the treatment effects during long-term, open-label treatment.
Conditions
- Huntington Disease
Interventions
pridopidineDrug
45mg bid
Primary outcomes
What the sponsor says the trial is designed to measure.
- Number of Patients With at Least One Adverse EventTime frame: From signing of the informed consent through the end of the follow-up period, which was defined as 30 days after the final study visit in an individual patient, an average of 2.8 years
Locations
No sites are listed on the registry yet.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.